Bristol-Myers Squibb Aktie News

Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

Bristol Myers Squibb Co. on Thursday reported better-than-expected first-quarter results, helped by strong sales of its top-selling blood thinner Eliquis. The drugmaker reported a net loss of $11.911 billion, or $5.89 per share, after net income of $2.262 billion, or $1.07 per share, in the year earlier period.

Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2024.

BMY has been upgraded to a Buy, with the stock already yielding 5.02% at the time of writing and the Seeking Alpha Quant still grading its dividend safety at B-. Combined with the promising profitability metrics and its overly discounted valuations, it now offers an attractive risk-reward ratio for value and dividend-oriented investors with long-term trajectory. We expect BMY to deliver a mixed...

In February, I recommended five one-month momentum plays to buy as Bitcoin ( BTC-USD ) prices surged. The world's largest cryptocurrency is a surprisingly good gauge of bubbly investor sentiment, and our writers at InvestorPlace.com had found several strong candidates to ride the market higher.

Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients.